Dr. Muhammad Din, Dr. Muhammad Wasim Awan, Dr. Shaghaf Iqbal, Dr. Zunaira Rafique, Dr. Samina Samina, Dr. Mansoor Ghani




OBJECTIVE: To determine the diagnostic accuracy of MRI in diagnosis of prostatic carcinoma in patients with raised PSA levels keeping histopathology as gold standard.

Materials and methods: This cross-sectional validation study was conducted in Department of Radiology KRL Hospital Islamabad, which is equipped with PHILIPS MULTIVA 1.5 TESLA MRI machine after taking permission from The Hospital Ethical Committee for six months  from 01-02-20 till 01-08-20. A total of 121 patients were selected with raised PSA levels, who later on underwent  MRI with different sequences including T1WI, T2WI, DWI, and dynamic contrast enhanced sequences after giving I/V contrast followed by biopsy and histopathology. Data was collected on a proforma and later on analyzed on SPSS Version 16 while the results were analyzed by descriptive and inferential statistics.


Out of 121 patients with mean age 51.23 years with the standard deviation of ±8.57. Out of 121 patients, sensitivity, specificity, positive predictive value, negative predictive value and diagnostic accuracy of MRI for the diagnosis of prostate carcinoma by taking histopathology as gold standard was found to be 92.3%, 82.7%, 94.4%, 77.4% and 90% respectively.


It is concluded that magnetic resonance imaging is a highly sensitive, specific and rapid method for diagnosing prostate cancer which has potential to complement the current reference standard of histopathology and increase its overall sensitivity.

KEY WORDS:  Prostate carcinoma, prostate specific antigen, magnetic resonance imaging and histopathology.

Full Text:




MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389:815-22.

Gaunay G, Patel V, Shah P, Moreira D, Hall SJ, et al. Role of multi-parametric MRI of the prostate for screening and staging: Experience with over 1500 cases. Asian J Urol . 2017 Jan; 4(1): 68-74.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.

Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, et al. Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:762–71.

Panebianco V, Barchetti F, Sciarra A, Ciardi A, Indino EL, Papalia R, et al. Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized study. Urol Oncol. 2015;33:17.e1–7.

Schimmöller L, Quentin M, Arsov C, Hiester A, Buchbender C, Rabenalt R, et al. MR-sequences for prostate cancer diagnostics: Validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol. 2014;24:2582–9.

Petrillo A, Fusco R, Setola SV, Ronza FM, Granata V, Petrillo M, et al. Multiparametric MRI for prostate cancer detection: Performance in patients with prostate-specific antigen values between 2.5 and 10 ng/mL. J Magn Reson Imaging. 2014;39:1206–12.

Gandaglia G, Leni R, Bray F, Fleshner N, Freedland SJ, Kibel A, Stattin P, Van Poppel H, La Vecchia C. Epidemiology and prevention of prostate cancer. European urology oncology. 2021 Dec 1;4(6):877-92.

Van Poppel H, Albreht T, Basu P, Hogenhout R, Collen S, Roobol M. Serum PSA-based early detection of prostate cancer in Europe and globally: past, present and future. Nature Reviews Urology. 2022 Sep;19(9):562-72.

Duffy MJ. Biomarkers for prostate cancer: prostate-specific antigen and beyond. Clinical Chemistry and Laboratory Medicine (CCLM). 2020 Feb 25;58(3):326-39.

Bass EJ, Pantovic A, Connor M, Gabe R, Padhani AR, Rockall A, Sokhi H, Tam H, Winkler M, Ahmed HU. A systematic review and meta-analysis of the diagnostic accuracy of biparametric prostate MRI for prostate cancer in men at risk. Prostate Cancer and Prostatic Diseases. 2021 Sep;24(3):596-611.

Ahmed HU, Bosaily AE, Brown LC, Gabe R, Kaplan R, Parmar MK, Collaco-Moraes Y, Ward K, Hindley RG, Freeman A, Kirkham AP. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet. 2017 Feb 25;389(10071):815-22.

Tavakoli AA, Hielscher T, Badura P, Görtz M, Kuder TA, Gnirs R, Schwab C, Hohenfellner M, Schlemmer HP, Bonekamp D. Contribution of dynamic contrast-enhanced and diffusion MRI to PI-RADS for detecting clinically significant prostate cancer. Radiology. 2023 Jan;306(1):186-99.

Yildirim K, Yildirim M, Eryesil H, Talo M, Yildirim O, Karabatak M, Ogras MS, Artas H, Acharya UR. Deep learning-based PI-RADS score estimation to detect prostate cancer using multiparametric magnetic resonance imaging. Computers and Electrical Engineering. 2022 Sep 1;102:108275.

Giambelluca D, Cannella R, Vernuccio F, Comelli A, Pavone A, Salvaggio L, Galia M, Midiri M, Lagalla R, Salvaggio G. PI-RADS 3 lesions: role of prostate MRI texture analysis in the identification of prostate cancer. Current problems in diagnostic radiology. 2021 Mar 1;50(2):175-85.

Kızılay F, Çelik S, Sözen S, Özveren B, Eskiçorapçı S, Özgen M, Özen H, Akdoğan B, Aslan G, Narter F, Çal Ç. Correlation of Prostate-Imaging Reporting and Data Scoring System scoring on multiparametric prostate magnetic resonance imaging with histopathological factors in radical prostatectomy material in Turkish prostate cancer patients: a multicenter study of the Urooncology Association. Prostate international. 2020 Mar 1;8(1):10-5.

Zhu G, Luo J, Ouyang Z, Cheng Z, Deng Y, Guan Y, Du G, Zhao F. The assessment of prostate cancer aggressiveness using a combination of quantitative diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging. Cancer Management and Research. 2021 Jul 2:5287-95.

Schieda N, Lim CS, Zabihollahy F, Abreu‐Gomez J, Krishna S, Woo S, Melkus G, Ukwatta E, Turkbey B. Quantitative prostate MRI. Journal of Magnetic Resonance Imaging. 2021 Jun;53(6):1632-45.

Drost FJ, Osses DF, Nieboer D, Steyerberg EW, Bangma CH, Roobol MJ, Schoots IG. Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews. 2019(4).


  • There are currently no refbacks.

© Copyright PJR 2008-